US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Ikena Oncology Inc (IKNA)
Ikena Oncology Inc (IKNA) ニュース

Ikena Oncology Inc (IKNA)

17.16

0.00

(0.00%)

終了 7月8日 5:00AM

17.16

0.00

( 0.00% )

プレマーケット: 9:00AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio

Shares of Ikena Oncology Inc. (NASDAQ:IKNA) rose 4.8% after the company announced that Kristin Yarema, Ph.D., will lead the soon-to-be-formed...

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and...

Form 8-K - Current report

Form D - Notice of Exempt Offering of Securities

Form 8-K - Current report

Form 8-K - Current report

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena...

Form 425 - Prospectuses and communications, business combinations

Monksdream

Monksdream 1年前

Monksdream

Monksdream 1年前

Monksdream

Monksdream 1年前

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

glenn1919

glenn1919 2年前

IKNA.....................................https://stockcharts.com/h-sc/ui?s=IKNA&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

herbied47

herbied47 3年前

$196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish

herbied47

herbied47 3年前

Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html

Tacostocks

Tacostocks 3年前

It went down, because it didnt have the backing of Money hunt...

Money hunt

Money hunt 3年前

what happened here my short friend

Tacostocks

Tacostocks 3年前

Aged like milk eh

AJ Freely

AJ Freely 3年前

$IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
To Acquire & Merge w/ Pionyr Immunotherapeutics

Tartiaboy

Tartiaboy 3年前

This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

I am not too familiar with there lead drug so I am neutral regarding it.

TrendTrade2016

TrendTrade2016 4年前

IKNA look at this beast

TrendTrade2016

TrendTrade2016 4年前

crudeoil24

crudeoil24 5年前

Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.

Shenzhen Expressway (PK)

Chocoladefabriken Lindt ... (PK)

DNB Bank ASA (PK)

Cypherpunk Technologies

Goldman Sachs Bank Usa P...

NBC Bancorp (ID)

Canadian Imperial Bank o...

7.500% Snr Nts 04/06/29 ...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。